جميع الدراسات
التوظيفالمرحلة 3تدخلي

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy

Researchers are looking for adults, aged 18 to 99, to take part in a study testing a new medicine called Maridebart Cafraglutide. This medicine is for people who have obstructive sleep apnea (OSA), which means their breathing repeatedly stops and starts during sleep. You also need to be using a positive airway pressure (PAP) machine, like a CPAP, and be overweight or have obesity. The study wants to find out if this new medicine can help improve your sleep apnea symptoms and if it's safe to use over about a year (52 weeks). Half the people in the study will get the new medicine, and the other half will get a placebo (a dummy medicine with no active ingredients).

نظرة سريعة

الحالة
التوظيف
المرحلة
المرحلة 3
الراعي
Amgen
الهدف من التسجيل
250
ابدأ
19 ديسمبر 2025
التاريخ المتوقع للانتهاء
13 Sep 2028

ما هو موضوع هذه الدراسة؟

This research study is about a new medicine called Maridebart Cafraglutide. It's being tested in adults who have a common sleep disorder called obstructive sleep apnea, often shortened to OSA. People with OSA find their breathing stops and starts repeatedly while they sleep because their airway becomes blocked. This can lead to poor sleep, tiredness during the day, and other health problems.

Many people with OSA already use a special machine, like a CPAP, to help them breathe better at night. This study is for those who use these machines and are also overweight or have obesity. The main goal is to see if adding this new medicine to their existing treatment can help improve their sleep apnea even more, and if it's safe to use over a long period, specifically 52 weeks (about a year).

If successful, this new medicine could offer another way to help people manage their obstructive sleep apnea, especially for those who are also dealing with overweight or obesity. It's an important step in finding more ways to help people get better rest and improve their overall health.

النقاط الرئيسية

  • This study is testing a new medicine for sleep apnea in adults.
  • Participants must use a PAP machine and be overweight or have obesity.
  • The study lasts about one year and involves regular clinic visits.
  • You might get the new medicine or a dummy medicine (placebo).
  • You'll have sleep tests, which may involve temporarily pausing PAP use.
  • It's important to discuss any concerns with the study team.

من قد يكون مؤهلاً؟

To join this study, you need to be an adult between 18 and 99 years old. You must have been diagnosed with obstructive sleep apnea (OSA) and your sleep test results should show a certain number of breathing pauses or shallow breaths per hour. You also need to be overweight or have obesity, based on your Body Mass Index (BMI).

Crucially, you must already be using a PAP machine (like a CPAP) for your sleep apnea and have been using it regularly for at least three months. You should also plan to continue using it throughout the study. Interestingly, you also need to have tried to lose weight through diet and exercise at least once before, even if it wasn't successful.

There are also some reasons why you might not be able to join. For example, if you've had surgery for your sleep apnea, have certain breathing problems like central sleep apnea, or other serious health conditions, you might not be suitable. Also, if you use other devices for your sleep apnea besides a PAP machine, you might need to stop using them to join the study.

هل يمكن أن تناسبك هذه الدراسة؟

أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.

  1. Are you between 18 and 99 years old?
  2. Have you been diagnosed with obstructive sleep apnea (OSA) and use a PAP machine?
  3. Have you been using a PAP machine consistently for at least 3 months?
  4. Are you overweight or have obesity (a BMI of 27 or more)?
  5. Have you tried to lose weight through diet and exercise before?
  6. Have you NOT had any surgery for sleep apnea or serious breathing problems like central sleep apnea?
أجب عن كل سؤال لترى نتيجتك.

ماذا يتضمن المشاركة؟

If you decide to take part, you'll be in the study for about 52 weeks, which is roughly one year. You'll be randomly assigned to either receive the new medicine, Maridebart Cafraglutide, or a placebo (a dummy medicine with no active ingredients). This decision is made by chance, like flipping a coin, and neither you nor the study team will know which you are receiving, to ensure fair results.

Throughout the study, you'll have regular visits to the clinic for health checks, to discuss any side effects, and to get your study medicine. You'll continue to use your PAP machine as usual. You'll also have some sleep tests (like polysomnography) at different times to see how your sleep apnea is changing. There will be a period during some of these tests where you might be asked to temporarily stop using your PAP machine for up to 7 days, to allow researchers to specifically measure the medicine's effect. The team will explain exactly what's involved at each step and how long each visit might take.

المخاطر والفوائد المحتملة

Participating in this study might offer potential benefits, such as potentially improving your sleep apnea symptoms with the new medicine. You'll also receive careful medical attention and monitoring throughout the study. However, there are potential risks, like experiencing side effects from the study medicine, which are not yet fully known. There's also no guarantee that the medicine will work for you. You have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (56)

  • Valley Clinical Trials
    الرمز البريدي المؤكد
    نورثريدج، الولايات المتحدة· التوظيف
  • Peninsula Research Associates
    الرمز البريدي المؤكد
    Rolling Hills Estates, United States· التوظيف
  • Teradan Clinical Trials
    الرمز البريدي المؤكد
    براندون، الولايات المتحدة· التوظيف
  • Destiny Research Center
    الرمز البريدي المؤكد
    Palmetto Bay, United States· التوظيف
  • Clinical Research Center Of Florida
    الرمز البريدي المؤكد
    Pompano Beach, United States· التوظيف
  • NeuroTrials Research
    الرمز البريدي المؤكد
    أتلانتا، الولايات المتحدة· التوظيف
  • Basil Clinical
    الرمز البريدي المؤكد
    Laurelton, United States· التوظيف
  • Monroe Biomedical Research
    الرمز البريدي المؤكد
    Monroe, United States· التوظيف
  • CTI Clinical Research Center
    الرمز البريدي المؤكد
    سينسيناتي، الولايات المتحدة· التوظيف
  • FutureSearch Trials of Neurology
    الرمز البريدي المؤكد
    أوستن، الولايات المتحدة· التوظيف
  • Epic Medical Research - DeSoto
    الرمز البريدي المؤكد
    DeSoto, United States· التوظيف
  • Sleep Therapy & Research Center
    الرمز البريدي المؤكد
    سان أنطونيو، الولايات المتحدة· التوظيف

أسئلة شائعة

What is Maridebart Cafraglutide?

It's a new medicine being tested in this study to see if it can help people with obstructive sleep apnea who also use a PAP machine and are overweight or have obesity.

ما هو "العلاج الوهمي"؟

A placebo is a dummy medicine that looks like the real medicine but contains no active ingredients. It's used to compare against the real medicine to see if it's truly effective.

Do I have to stop using my CPAP machine?

You'll continue using your CPAP machine normally, but for some specific sleep tests during the study, you might be asked to stop using it for up to 7 days.

كم ستستغرق مدة الدراسة؟

The study will last for about 52 weeks, which is roughly one year.

هل يمكنني مغادرة الدراسة في أي وقت؟

Yes, you have the right to stop participating in the study at any point, for any reason. Your medical care won't be affected if you choose to withdraw.

كيفية معرفة المزيد

Amgen Call Center

تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.

هل أنت مهتم بالمشاركة؟

سجل اهتمامك

شارك تفاصيلك وفريق البحث لـ "Maridebart Cafraglutide Versus Placebo in Adult Participants… "سيتواصل معك إذا كنت مؤهلاً. تحدث دائمًا إلى طبيبك قبل الموافقة على المشاركة.

نقاش

مناقشة المجتمع

مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.